LifeVantage Corporation has entered a definitive agreement to acquire the critical operating assets of LoveBiome, a direct-sales company specializing in microbiome health and wellness solutions.
LoveBiome’s P84 product, designed to regulate, repair, and restore the gut and microbiome, will complement LifeVantage’s existing range of scientifically validated activators, including the Protandim® family and the MindBody GLP-1 System™, the company said that. The acquisition is intended to strengthen LifeVantage’s Activation-based differentiation and expand its consultant network across key markets such as the U.S., Taiwan, and Europe, according to the company.
LifeVantage claims the global gut-health supplement market is expected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, at a compound annual growth rate of 8.4 percent. The company said that the acquisition is expected to be accretive to adjusted EPS and adjusted EBITDA in its first year, with further synergy potential.
Under the agreement, LoveBiome’s founder and CEO, Kelly Olsen, and other key personnel will join LifeVantage to ensure operational continuity. The transaction is expected to close by mid-October, subject to customary closing conditions and regulatory approvals.
